A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2001
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409148A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/22/2001	CA2409116A1 Substituted thioacetamides
11/22/2001	CA2409108A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2408849A1 Cyclohexane derivatives and their use as therapeutic agents
11/22/2001	CA2408842A1 Method for treating retinal degeneration with purinergic receptor agonists
11/22/2001	CA2408827A1 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408513A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2408374A1 Mutation in the .beta.2 nicotinic acetylcholine receptor subunit associated with nocturnal frontal lobe epilepsy
11/22/2001	CA2408360A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2407259A1 Polyketide derivatives
11/22/2001	CA2407258A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	CA2407099A1 Aralkyl ester soft drugs
11/22/2001	CA2407088A1 Beta-secretase inhibitors
11/21/2001	EP1156332A2 Assay methods for cyclin dependent kinases
11/21/2001	EP1156110A2 G-protein coupled receptor (HFGAN72Y)
11/21/2001	EP1156049A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
11/21/2001	EP1156047A1 6-substituted-7- heteroquinoxaline carboxylic acid derivatives and addition salts thereof and processes for the preparation of both
11/21/2001	EP1156044A1 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
11/21/2001	EP1156043A2 Drugs that enhance synaptic responses mediated by ampa receptors
11/21/2001	EP1156040A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
11/21/2001	EP1155696A2 Use of olanzapine for the manufacture of a medicament for neuroprotection
11/21/2001	EP1155304A2 A system for cell-based screening
11/21/2001	EP1155016A1 Process for the production of paroxetine hydrochloride acetone solvate
11/21/2001	EP1155000A1 2-aminopyridines containing fused ring substituents
11/21/2001	EP1154996A2 Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain
11/21/2001	EP1154988A1 Mevinolin derivatives
11/21/2001	EP1154987A1 Phenylalaninol derivatives
11/21/2001	EP1154984A1 Inhibitors for uptake of serotonine, dopamine or norepinephrine
11/21/2001	EP1154983A1 Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
11/21/2001	EP1154803A1 Immobilized labeling compounds and methods
11/21/2001	EP1154801A1 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients
11/21/2001	EP1154794A1 Agent containing an additional local anaesthetic for the treatment of symptoms of parkinson's disease
11/21/2001	EP1154776A1 Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
11/21/2001	EP1154773A2 Use of antagonists of pg-e for the treatment of neuropathic pain
11/21/2001	EP0873340B1 Heterocyclic substituted cyclopentane compounds
11/21/2001	EP0833638B1 USE OF IMIDAZO 1,5-a]QUINOLONES AS NEUROPROTECTIVE AGENTS
11/21/2001	EP0745081B1 indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
11/21/2001	EP0719773B1 Imidazolidinone derivative, acid-addition salt thereof, and remedy for senile dementia
11/21/2001	EP0641328B1 Bridged aza-bicyclic derivatives as substance p antagonists
11/21/2001	CN1323314A Inhibitors of caspases
11/21/2001	CN1323302A N-cimidazolylalkyl) substituted cyclic amines as histamine-H3 agonists or antagonists
11/21/2001	CN1323301A Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
11/21/2001	CN1323294A Cyclic ester or amide derivatives
11/21/2001	CN1323291A Diaminopropionic acid derivatives
11/21/2001	CN1323289A Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
11/21/2001	CN1323211A New pharmaceutical uses for NOS inhibitors
11/21/2001	CN1323210A Method for treating schizophrenia and means used in said method
11/21/2001	CN1323205A Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
11/21/2001	CN1323202A Sertraline oral concentrate
11/21/2001	CN1323201A Extended release buccal bioadhesive tablet
11/21/2001	CN1323165A Protein material for slow digestion and its use
11/21/2001	CN1322725A Indole derivant
11/21/2001	CN1322526A Compound for treating female sexual dysfunction
11/21/2001	CN1322524A Use of pentanoate derivant
11/21/2001	CN1075072C Oxazolidinone derivatives their preparation and use
11/21/2001	CN1075070C Substituted A2a-and diazacycloheptane and cyclooctane compounds and their use
11/21/2001	CN1075067C Furan and furan amide compound and producing process and pharmaceutical composition thereof
11/21/2001	CN1075059C Colchicine derivatives and its therapeutical use
11/21/2001	CN1074927C Active medical component of 'Duanshepiju' its extraction process and medicine containing the same
11/21/2001	CN1074922C Oral liquid composition containing paroxetine resinate
11/21/2001	CN1074920C Analgesic agent and its use
11/21/2001	CN1074919C Application of levobupivacaine for treating chronic pain
11/21/2001	CN1074918C Use of Ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motion blockade
11/20/2001	US6321105 Method for diagnosing neurological, neurodegenerative and psychiatric diseases by magnetic resonance imaging using contrast agents with high magnetic susceptibility and extended plasma half life
11/20/2001	US6320038 Promoter for neuropeptide FF and use thereof for therapy and diagnostics
11/20/2001	US6320022 Adrenomedullin peptides
11/20/2001	US6319944 Nmda nr2b antagonists; neurological and neurodegenerative diseases including pain, (and in particular neuropathic pain), epilepsy, stroke, anxiety, cerebral ischemia, muscular spasms, alzheimer's, huntington's and parkinson's diseases
11/20/2001	US6319935 Used in treatment of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity
11/20/2001	US6319930 Substituted dimeric compounds
11/20/2001	US6319926 Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it
11/20/2001	US6319924 For therapy of deleterious mental states
11/20/2001	US6319921 Aromatic heterocyclic compound as antiinflammatory agents
11/20/2001	US6319920 Muscarinic receptor antagonist used in gastrointestinal, genitourinary tract, respiratory tract, cardiovascular system, central nervous system disorders and in anesthesiology and ophthalmology
11/20/2001	US6319917 Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
11/20/2001	US6319910 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
11/20/2001	US6319903 Anticonvulsant derivatives useful in treating cluster headaches
11/20/2001	US6319689 Nucleotide sequence which code aspartic protease; for treatment of alzheimer's disease, cancer; for hormone processing
11/20/2001	US6319687 Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
11/20/2001	US6319686 Nucleotide sequences coding binding protein; for use as diagnostic, drug design and therapeutic tools
11/20/2001	US6319513 Oral liquid mucoadhesive compounds
11/20/2001	US6319510 Pad to be installed on gum comprising nonporous layer, adjacent layer retaining medication capable of being liquefied by saliva, semipermeable layer covering second layer and sealed to first layer to form pocket enclosing second layer
11/20/2001	US6319505 Administering to patient suffering from tardive dyskinesia effective amount of botulinum toxin selected from types c, e, and g, thereby alleviating symptoms
11/20/2001	US6319498 Amyloidogenic protein, or fragment thereof, modified with cis-decalin group, cholanoyl structure, cholyl group, diethylenetriaminepentaacetyl group, menthoxyacetyl group, fluorescein-containing group, or n-acetylneuraminyl group
11/20/2001	CA2297163C Gaba analogs to prevent and treat gastrointestinal damage
11/20/2001	CA2257431C Fast-dissolving galanthamine hydrobromide tablet
11/20/2001	CA2025599C Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
11/19/2001	CA2324167A1 A membrane-bound netrin
11/19/2001	CA2308994A1 Neuroprotective compounds
11/15/2001	WO2001085995A2 Identification of neural defects associated with the nucleosom al assembly protein 1l2 gene
11/15/2001	WO2001085980A2 Enzymatic assays for screening anti-cancer agents
11/15/2001	WO2001085959A2 Regulation of human lysostaphin-like protease
11/15/2001	WO2001085956A2 Lipid metabolism enzymes
11/15/2001	WO2001085942A2 Cytoskeleton-associated proteins
11/15/2001	WO2001085940A2 USE OF hTAFII80 AND ISOFORMS THEREOF FOR INDUCING APOPTOSIS
11/15/2001	WO2001085937A2 Regulator of g protein signalling (rgs8)

1 ... 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 ... 1833